Sanofi (SNY) Expected to Post Earnings on Friday

Sanofi (NASDAQ:SNY) is expected to be issuing its Q3 2026 results before the market opens on Friday, October 30th. Analysts expect Sanofi to post earnings of $1.63 per share and revenue of $14.80 billion for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, October 30, 2026 at 8:30 AM ET.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Thursday, July 30th. The company reported $2.41 earnings per share (EPS) for the quarter. The business had revenue of $13.36 billion during the quarter. During the same quarter last year, the firm posted $3.24 earnings per share. The company’s revenue was up 16.0% compared to the same quarter last year. On average, analysts expect Sanofi to post $5.00 EPS for the current fiscal year and $5.19 EPS for the next fiscal year.

Sanofi Price Performance

NASDAQ SNY opened at $41.89 on Wednesday. Sanofi has a 12 month low of $39.07 and a 12 month high of $52.68. The company has a 50-day moving average of $42.33 and a 200-day moving average of $44.43. The company has a market cap of $101.56 billion, a P/E ratio of 21.93 and a beta of 0.33.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Morgan Stanley set a $49.00 price target on shares of Sanofi in a research report on Wednesday, July 8th. Royal Bank Of Canada assumed coverage on shares of Sanofi in a report on Tuesday, September 8th. They issued a “sector perform” rating on the stock. Wolfe Research assumed coverage on shares of Sanofi in a research note on Friday, October 9th. They set a “peer perform” rating for the company. Weiss Ratings upgraded Sanofi from a “sell (d)” rating to a “sell (d+)” rating in a report on Thursday, October 8th. Finally, HSBC reaffirmed a “buy” rating on shares of Sanofi in a research report on Thursday, September 10th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $49.50.

About Sanofi

Sanofi is a France-based global healthcare company that researches, develops, manufactures and markets prescription medicines and vaccines. Its operations focus primarily on specialty medicines, immunology, rare diseases, neurology, oncology and treatments for rare blood disorders, as well as established pharmaceutical products.

The company’s portfolio includes Dupixent, an immunology medicine developed with Regeneron; vaccines for influenza, polio, meningitis and other infectious diseases; and treatments for conditions including multiple sclerosis, hemophilia and certain rare diseases.